Market Cap | 241.86M | P/E | - | EPS this Y | 18.00% | Ern Qtrly Grth | - |
Income | -78.98M | Forward P/E | -3.96 | EPS next Y | 21.00% | 50D Avg Chg | -11.00% |
Sales | 62.37M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 9.00% |
Dividend | N/A | Price/Book | 1.31 | EPS next 5Y | - | 52W High Chg | -35.00% |
Recommedations | 1.70 | Quick Ratio | 3.89 | Shares Outstanding | 65.30M | 52W Low Chg | 123.00% |
Insider Own | 5.92% | ROA | -20.78% | Shares Float | 46.15M | Beta | 1.18 |
Inst Own | 50.02% | ROE | -44.93% | Shares Shorted/Prior | 46.32K/43.01K | Price | 3.76 |
Gross Margin | 68.80% | Profit Margin | -126.63% | Avg. Volume | 65,309 | Target Price | 8.67 |
Oper. Margin | -110.98% | Earnings Date | May 7 | Volume | 41,974 | Change | 3.58% |
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
BTIG | Buy | Mar 6, 24 |
RBC Capital | Outperform | Mar 6, 24 |
RBC Capital | Outperform | Jan 12, 24 |
RBC Capital | Outperform | Nov 29, 23 |
Credit Suisse | Neutral | May 10, 23 |
Morgan Stanley | Overweight | May 10, 23 |
Morgan Stanley | Overweight | Mar 8, 23 |
BTIG | Buy | Jan 3, 23 |
Credit Suisse | Neutral | Nov 23, 22 |